Mesa Laboratories (NASDAQ:MLAB) Issues Earnings Results, Misses Estimates By $1.54 EPS

Mesa Laboratories (NASDAQ:MLAB) released its quarterly earnings results on Monday. The medical instruments supplier reported $0.75 EPS for the quarter, missing the consensus estimate of $2.29 by ($1.54), FiscalAI reports. The firm had revenue of $62.34 million for the quarter, compared to analyst estimates of $62.20 million. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Here are the key takeaways from Mesa Laboratories’ conference call:

• Organic revenue growth accelerated to 2.6% in Q2 from 1% in Q1, and was about 5% excluding Clinical Genomics. Sterilization and Disinfection Control grew in the mid-teens and Calibration Solutions about 3.5%, while Biopharmaceutical Development declined 8.2% due to export-control delays and shipments that moved into Q3.
• Fiscal 2027 guidance calls for $250 million–$255 million in revenue and $66 million–$68 million in adjusted EBITDA, implying EBITDA growth of 5%–8% even as revenue grows 0%–2%. Management said the outlook includes Clinical Genomics’ revenue reset and restructuring-plan reinvestments, and was set conservatively.
• SDC grew 14.6% organically in Q2, largely reflecting a comparison with prior-year delivery delays, and its trailing 12-month revenue reached a record $103.9 million. However, a key product line responsible for much of the past-due backlog is only partially fixed, leaving a significant delivery-reliability issue unresolved.
• Mesa is restructuring Clinical Genomics to focus on pharmacogenomics, oncology, and high-utilization customer accounts; revenue is expected to be lower, but management expects profitability to improve and cited multiyear renewals from its three largest customers. The company expects about $9.3 million in annualized gross cost savings, reinvesting $4.3 million for a net reduction of about $5 million.
• Mesa repaid $20.1 million of debt in the first half and ended the quarter at 1.75x net leverage, within its target range. The board also authorized share repurchases of up to $40 million through December 2028, while management said debt reduction and investment in higher-return businesses remain priorities.

Mesa Laboratories Stock Performance

MLAB stock traded down $0.43 during trading on Monday, hitting $127.82. The company had a trading volume of 118,371 shares, compared to its average volume of 140,603. The firm has a market cap of $715.79 million, a PE ratio of 152.17 and a beta of 1.08. Mesa Laboratories has a 1-year low of $69.51 and a 1-year high of $144.35. The firm has a 50-day moving average price of $128.30 and a 200-day moving average price of $104.95. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 30th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.5%. The ex-dividend date is Monday, November 30th. Mesa Laboratories’s payout ratio is 76.19%.

Insiders Place Their Bets

In other Mesa Laboratories news, Director John Sullivan sold 7,093 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $112.80, for a total transaction of $800,090.40. Following the completion of the sale, the director directly owned 17,834 shares of the company’s stock, valued at approximately $2,011,675.20. This trade represents a 28.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Siddhartha Kadia bought 7,093 shares of the stock in a transaction on Thursday, August 13th. The stock was bought at an average price of $112.80 per share, for a total transaction of $800,090.40. Following the completion of the purchase, the chief executive officer directly owned 7,093 shares in the company, valued at approximately $800,090.40. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. 2.80% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on MLAB. Wells Fargo & Company boosted their price objective on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Weiss Ratings upgraded shares of Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 3rd. Three research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $110.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company’s offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.

Mesa Laboratories’ product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings.